Lasa Supergenerics Peer Comparison

NSE: LASA | BSE: 540702

₹4.91

₹-0.25 (-4.84%)

As on 19-Oct-2026IST

Market cap

₹27 Cr

Revenue (TTM)

₹6 Cr

P/E Ratio

P/B Ratio

0.6

Div. Yield

0 %

Edit

	Lasa Supergenerics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	27	33,547	24,280	15,313	12,856
Revenue (₹ Cr)	6	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	-16.55	1,018.97	497.77	603.02	270.18
Net Margin (%)	-253.90	10.47	20.72	22.63	23.29
RoE (%)	-29.40	21.30	28.49	19.61	14.45
Price to Earnings	--	33.17	48.78	25.39	46.68
Price-To-Book	0.58	6.41	12.01	4.39	6.20

Income Statement (₹ Cr)

	Lasa Supergenerics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	6.36	9,683.45	2,371.81	2,590.40	1,108.39
Total Income	6.52	9,730.84	2,402.61	2,664.23	1,159.90
Total Expenditure	14.61	7,739.53	1,608.91	1,753.71	720.01
EBITDA	-8.26	1,943.92	762.90	836.69	388.38
Depreciation	6.01	425.10	98.11	78.88	74.78
EBIT	-14.27	1,518.82	664.79	757.81	313.60
Interest	0.50	148.45	26.33	5.43	0.26
Other Income	0.17	47.39	30.80	73.83	51.50
Exceptional Items	-0.94	-27.85	0.00	-25.66	-3.28
Profit before Tax	-15.55	1,389.91	669.26	800.55	361.56
Provision for Tax	1.01	370.94	171.48	197.53	91.39
Profit after Tax	-16.55	1,018.97	497.77	603.02	270.18

	Lasa Supergenerics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	49.62	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	0.00	-7.58	0.00	0.00	2.51
Non-Current Liabilities	-0.12	723.57	345.47	142.73	50.51
Current Liabilities	16.77	3,912.24	710.20	508.04	169.08
Total Liabilities	150.87	7,709.37	1,832.56	3,528.05	1,700.71

	Lasa Supergenerics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	55.05	3,392.16	1,290.62	1,321.38	957.22
Current Assets	10.44	5,612.10	1,483.13	2,649.36	1,250.11
Total Assets	150.87	7,709.37	1,832.56	3,528.05	1,700.71
Total Debt*	22.08	2,072.49	82.51	0.00	6.23
Net Current Assets	-6.34	1,699.86	772.93	2,141.33	1,081.04
Contingent Liabilities	--	285.51	27.73	4.82	14.31

	Lasa Supergenerics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	2.14	1,097.24	261.18	413.52	265.47
Cash Flow from Investing Activities	-0.40	-712.51	-149.69	-116.48	-154.61
Cash from Financing Activities	-1.93	-164.21	-69.28	-279.44	-99.21
Net Cash Inflow / Outflow	-0.19	220.52	42.21	17.59	11.64

	Lasa Supergenerics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	-13.23	19.87	33.51	28.31	29.13
ROE (%)	-29.40	21.30	28.49	19.61	14.45
ROA (%)	-19.73	11.42	19.48	16.31	12.66
EBIT Margin (%)	-224.58	15.68	28.03	29.25	28.29
Net Margin (%)	-253.90	10.47	20.72	22.63	23.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Lasa Supergenerics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	-95.17	18.36	78.33	7.93	-6.72
EBIT Growth (%)	-100.70	30.43	303.07	19.88	-26.64
Net Profit Growth (%)	50.06	32.39	182.61	21.66	-24.38
EPS Growth (%)	-164.28	36.68	277.72	25.42	-21.99
Book Value Growth (%)	-18.27	18.16	29.06	8.90	18.34

	Lasa Supergenerics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	0.00	32.49	48.78	24.59	46.28
Price / Book Value	1.14	6.41	12.01	4.39	6.20
Dividend Yield (%)	0.00	0.20	0.18	0.40	0.61
EV/EBITDA	56.20	17.80	31.62	17.37	32.03
Market Cap (₹ Cr)	110.07	0.00	8,058.80	9,499.31	15,922.01

	Lasa Supergenerics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.00	0.05	0.09	0.00	0.00
Short term debt to equity ratio	--	0.32	--	--	--
Current Ratio	0.62	1.43	2.09	5.21	7.39
Quick Ratio	0.51	0.82	1.37	3.85	5.46
Interest Coverage	-30.16	10.36	26.41	148.49	1,386.30

	Lasa Supergenerics	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	0.65	26.46	22.82	41.42	41.52
Asset Turnover	0.08	1.09	0.93	0.70	0.52
Receivable days	10.61	94.32	86.10	125.30	111.87
Inventory Days	57.63	78.21	73.73	101.28	75.42
Payable days	56.97	193.72	114.75	149.95	149.88
Cash Conversion Cycle	11.27	-21.19	45.08	76.63	37.41

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.